Pre-synaptic glutamate-induced activation of da release in the striatum after partial nigral lesion

Journal of Neurochemistry

Volumn 113, Issue 6, 2010, Pages 1459-1470

  Dzahini, Kwamivi ^a,b,c,d   Dentresangle, Christine ^e   Le Cavorsin, Marion ^e   Bertrand, Anne ^c,d   Detraz, Isabelle ^c,d   Savasta, Marc ^c,d   Leviel, Vincent ^a,b  

^a STEM CELL AND BRAIN RESEARCH INSTITUTE   (France)

^b UNIVERSITÉ DE LYON   (France)

^c GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^d UNIV GRENOBLE ALPES   (France)

^e CNRS   (France)

Author keywords

Dopamine; Glutamate; Microdialysis; Parkinson's disease; Striatum; Voltammetry

Indexed keywords

4 AMINOBUTYRIC ACID; 6 HYDROXYTRYPTAMINE; AMANTADINE; ASCORBIC ACID; ASPARTIC ACID; DOPAMINE; GLUTAMIC ACID; MEMANTINE; OXIDOPAMINE; RILUZOLE; VANOXERINE;

AMINO ACID ANALYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; MICRODIALYSIS; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; POTENTIOMETRY; PRESYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN METABOLISM; PUTAMEN; RAT; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA;

ANIMALIA; RATTUS;

EID: 77953116142     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06682.x     Document Type: Article

References (78)

1. Albe-Fessard D., Stutinsky F. Libouban S. (1971) Atlas stéréotaxique du diencephale du rat blanc. Editions du CNRS
2. Altar C., Marien M. Marshall J. (1987) Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J. Neurochem. 48, 390 399.
3. Amalric M., Baunez C. Nieoullon A. (1995) Does the blockade of excitatory amino acid transmission in the basal ganglia simply reverse reaction time deficits induced by dopamine inactivation? Behav. Pharmacol. 5 and 6, 508 519.
4. Aymerich M., Barroso-Chinea P., Pérez-Manso M., Muñoz-Patiño A., Moreno-Igoa M., González-Hernández T. Lanciego J. (2006) Consequences of unilateral nigrostriatal denervation on the thalamostriatal pathway in rats. Eur. J. Neurosci. 23, 2099 2108.
5. Bannon M., Michelhaugh S., Wang J. Sacchetti P. (2001) The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur. Neuropsychopharmacol. 11, 449 455.
6. Barnéoud P., Mazadier M., Miquet J. M., Parmentier S., Dubédat P., Doble A. Boireau A. (1996) Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience 74, 971 983.
7. Benazzouz A., Gross C., Feger J., Boraud T. Bioulac B. (1993) Reversal of rigidity and improvement in motor performance by subthalamic high frequency stimulation in MPTP-treated monkeys. Eur. J. Neurosci. 5, 382 389.
8. Benazzouz A., Boraud T., Dubédat P., Boireau A, Stutzmann J. M. Gross C. (1995) Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur. J. Pharmacol. 284, 299 307.
9. Bezard E., Boraud T., Bioulac B. Gross C. (1997) Compensatory effects of glutamatergic inputs to the substantia nigra pars compacta in experimental parkinsonism. Neuroscience 81, 399 404.
10. Blanchard V., Chritin M., Vyas S., Savasta M., Feuerstein C., Agid Y., Javoy-Agid Y. Raisman-Vozari R. (1995) Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain. J. Neurochem. 64, 1669 1679.
11. + induced increase in striatal extracellular dopamine in vivo. Neuroreport 5, 2157 2160.
12. Boulet S., Mounayar S., Poupard A. et al. (2008) Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. J. Neurosci. 28, 9575 9584.
13. Calabresi P., Mercuri N., Sancesario G. Bernardi G. (1993) Electrophysiology of dopamine denervated striatal neurons: implications for Parkinson's disease. Brain 116, 433 452.
14. Calabresi P., Pisani A., Mercuri N. Bernardi G. (1996) The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. 19, 19 24.
15. Castaneda E., Whishaw I. Robinson T. (1990) Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size. J. Neurosci. 10, 1847 1854.
16. Cepeda C., Hurst R., Altemus K. et al. (2001) Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J. Neurophysiol. 85, 659 670.
17. Chen H. Lipton S. (1997) Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J. Physiol. 499, 27 46.
18. Chen H., Pellegrini J., Aggarwal S., Lei S., Warach S., Jensen F. Lipton S. (1992) Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. 12, 4427 4436.
19. Chéramy A., Romo R., Godeheu G., Baruch P. Glowinski J. (1986) In vivo presynaptic control of dopamine release in the cat caudate nucleus - II. Facilitatory or inhibitory influence of L-glutamate. Neuroscience 19, 1081 1090. (Pubitemid 17217005)
20. Chéramy A., Desce J., Godeheu G. Glowinski J. (1994) Presynaptic control of dopamine synthesis and release by excitatory amino acids in rat striatal synaptosomes. Neurochem. Int. 25, 145 154. (Pubitemid 24273630)
21. Cremers T., de Vries M., Huinink K., van Loon J., Hart M., Ebert B., Westerink ben H. de Lange E. (2009) Quantitative microdialysis using modified ultraslow microdialysis: direct rapid and reliable determination of free brain concentrations with the metaquant technique. J. Neurosci. Methods 178, 249 254.
22. Danysz W., Gossel M., Zajaczkowski W., Dill D. Quack G. (1994) Are NMDA antagonistic properties relevant for antiparkinsonian activity in rats? Case of amantadine and memantine. J. Neural. Transm. - Parkinson Sect. 7, 155 166.
23. Danysz W., Parsons C., Kornhuber J., Schmidt W. Quack G. (1997) Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci. Biobehav. Rev. 21, 455 468.
24. Dentresangle C., Le Cavorsin M., Savasta M. Leviel V. (2001) Increased extracellular DA and normal evoked DA release in the rat striatum after a partial lesion of the substantia nigra. Brain Res. 893, 178 185.
25. Desce J. M., Godeheu G., Galli T., Glowinski J. Chéramy A. (1994) Opposite presynaptic regulations by glutamate through NMDA receptors of dopamine synthesis and release in rat striatal synaptosomes. Brain Res. 640, 205 214. (Pubitemid 24086548)
26. Doble A. (1996) The pharmacology and mechanism of action of riluzole. Neurology 47, S233 S241.
27. Emmi A., Rajabi H. Stewart J. (1996) Behavioral and neurochemical recovery from partial 6-Hydroxydopamine lesions of the substantia nigra is blocked by daily treatment with glutamate receptor antagonists MK-801 and CPP. J. Neurosci. 16, 5216 5224.
28. Erdo S. Schafer M. (1991) Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate an Nmethyl D aspartate; Eur. J. Pharmacol. 198, 215 217.
29. Gianutsos G., Chute S. Dunn J. P. (1985) Pharmacological changes in dopaminergic systems induced by long term administration of amantadine. Eur. J. Pharmacol. 110, 357 361.
30. Gonon F., Navarre F. Buda M. (1984) In vivo monitoring of dopamine release in the rat brain with differential normal pulse voltammetry. Anal. Chem. 56, 573 575.
31. Grace A. (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: an hypothesis for the etiology of schizophrenia. Neuroscience 41, 1 24.
32. Grace A. (2008) Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy. Mov. Disord. 23 (Suppl 3 S560 S569.
33. Greenamyre J. O'Brien C. (1991) N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch. Neurol. 48, 977 981.
34. Hefti F., Enz A. Melamed E. (1985) Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology 24, 19 23.
35. Hollerman J. Grace A. (1990) The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons. Brain Res. 533, 203 212.
36. Johnson K. Jeng Y. (1991) Pharmacological evidence for N-methyl-D-aspartate receptors on nigrostriatal dopaminergic nerve terminals. Can. J. Physiol. Pharmacol. 69, 1416 1421.
37. Kashani A., Betancur C., Giros B., Hirsch E. El Mestikawy S. (2006) Altered expression of vesicular glutamate transporters VCGLUT1 and VGLUT2 in Parkinson disease. Neurobiol. Aging 28, 568 578.
38. Keefe K., Zigmond M. Abercrombie E. (1992) Extracellular dopamine in striatum: influence of nerve impulse activity in medial forebrain bundle and local glutamatergic input. Neuroscience 47, 325 332.
39. Kornhuber J., Bormann J., Hubers M., Rushe K. Riederer P. (1991) Effects of the l-amino-adamantanes at the (+)-MK-801-bindingsite of the NMDA -receptor gated ion channel- a human post mortem brain study. Eur. J. Pharmacol. 206, 297 300.
40. Krebs M. O., Desce J. M., Kemel M. L., Gauchy C., Godeheu G., Cheramy A. Glowinski J. (1991) Glutamatergic control of dopamine release in the rat striatum: evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals. J. Neurochem. 56, 81 85.
41. + currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur. J. Neurosci. 27, 2501 2514.
42. Lange K., Kornhuber J. Riederer P. (1997) Dopamine/glutamate interactions in Parkinson's disease. Neurosci. Biobehav. Rev. 21, 393 400.
43. Leviel V. (2001) The reverse transport of DA, what physiological significance. Neurochem. Int. 38, 83 106.
44. Leviel V., Gobert A. Guibert B. (1989) Direct observation of dopamine compartmentation in striatal nerve terminal by 'in vivo' measurement of the specific activity of released dopamine. Brain Res. 499, 205 213.
45. Leviel V., Gobert A. Guibert B. (1990) The glutamate mediated release of dopamine in the rat striatum: further characterisation of the dual excitatory/inhibitory function. Neuroscience 39, 305 312.
46. Lindefors N. Ungerstedt U. (1990) Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci. Lett. 115, 248 252.
47. Lipton S. (2006) Paradigm shifts in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 5, 160 170.
48. Mantz J., Chéramy A., Thierry A., Glowinski J. Desmonts J. (1992) Anesthetic properties of riluzole (54274 RP), a new inhibitor of glutamate neurotransmission. Anesthesiology 76, 844 848.
49. McCallum S., Parameswaran N., Perez X., Bao S., McIntosh J., Grady S. Quik M. (2006) Compensation in pre-synaptic dopaminergic function following nigrostriatal damage in primates. J. Neurochem. 96, 960 972.
50. Mortensen O. Amara S. (2003) Dynamic regulation of the dopamine transporter. Eur. J. Pharmacol. 479, 159 170.
51. Nastuk W., Su P. Doubilet P. (1976) Anticholinergic and membrane activitiesof amantadine in neuromuscular transmission. Nature 264, 76 79.
52. Nieoullon A, Cheramy A Glowinski J. (1978) Release of dopamine in both caudate nuclei and both substantia nigrae in response to unilateral stimulation of cerebellar nuclei in the cat. Brain Res. 148, 143 152. (Pubitemid 8344489)
53. Oh J., Russel D., Vaughan C. Chase T. (1998) Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res. 813, 150 159.
54. Olivier V., Guibert B. Leviel V. (1995) Direct in vivo comparison of two mechanisms releasing dopamine in the rat striatum. Brain Res. 695, 1 9.
55. Olivier V., Gobert A., Guibert B. Leviel V. (1999) The in vivo modulation of dopamine synthesis by calcium ions: Influences on the calcium independent release. Neurochem. Int. 35, 431 438.
56. Olson R. Justice J. Jr. (1993) Quantitative microdialysis under transcient conditions. Anal. Chem. 68, 1017 1022.
57. Parsons C., Gruner R., Rozenthal J., Millar J. Lodge D. (1993) Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyl-adamantan). Neuropharmacology 32, 1337 1350.
58. Parsons C., Quack G., Bresink I., Baran L., Przegalinski E., Kostowski W., Krzascik P., Hartmann S. Danysz W. (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34, 1239 1258.
59. Perez X., Parameswaran N., Huang L., O'Leary K. Quik M. (2008) Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non human primates. J. Neurochem. 105, 1861 1872.
60. Phillips J., Lam H., Ackerson L. Maidment N. (2006) Blockade of mGlur5 glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease. Eur. J. Neurosci. 23, 151 160.
61. Raju D., Ahern T., Shah D., Wright T., Standaert D., Hall R. Smith Y. (2008) Differential synaptic plasticity of the corticostriatal and thalamostriatal systems in an MPTP-treated monkey model of parkinsonism. Eur. J. Neurosci. 27, 1647 1658.
62. Richard M. Bennett J. (1995) NMDA receptor blockade increases in vivo striatal dopamine synthesis and release in rats and mice with incomplete, dopamine depleting, nigrostriatal lesions. J. Neurochem. 64, 2080 2086.
63. Robinson T. Whishaw I. (1988) Normalisation of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra : a microdialysis study in freely moving rats. Brain Res. 45, 209 224.
64. Romo R., Chéramy A., Godeheu G. Glowinski J. (1986) In vivo presynaptic control of dopamine release in the cat caudate nucleus- III. Further evidence for the implication of corticostriatal glutamatergic neurons. Neuroscience 19, 1091 1099.
65. Samuel D., Errami M. Nieoullon A. (1990) Localization of N-methyl-D-aspartate receptors in the rat striatum: effects of specific lesions on the [3H]3-(2-carboxypiperazin-4)propyl-1-phosphonicacid binding. J. Neurochem. 54, 1926 1933.
66. Schwab R. S., England A. Jr. Poskanser D. (1969) Amantadine in the treatment of Parkinson's disease. JAMA 208, 1168 1170.
67. Sonsalla P., Nicklas W. Heikkila R. (1989) Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science 243, 398 400.
68. Stachowiak M., Keller R., Stricker E. Zigmond M. (1987) Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage. J. Neurosci. 7, 1648 1654.
69. Standaert D., Testa C., Rudolph G. Hollingsworth Z. (1996) Inhibition of N-methyl-D-aspartate glutamate receptor sub-unit expression by antisens oligonucleotids reveals their role in striatal motor regulation. J. Pharmacol. Exp. Therap. 276, 342 352.
70. Storch A., Burkhardt K. Ludolph A. (2000) Protective effect of riluzol on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J. Neurochem. 75, 2259 2269.
71. Tang K., Low M., Grandy D. Lovinger D. (2001) Dopamine dependent synaptic plasticity in striatum during in vivo development. Proc. Natl Acad. Sci. USA 98, 1255 1260.
72. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349, 414 418.
73. Ulas J. Cotman C. (1996) Dopaminergic denervation of striatum results in elevated expression of NR2A subunit. Neuroreport 7, 1789 1793.
74. Wang J. (1991) Presynaptic glutamate receptors modulate dopamine release from striatal synaptosomes. J. Neurochem. 57, 819 822.
75. Wullner U., Testa C., Catania M., Young A. Penney J. Jr. (1994) Glutamate receptors in striatum and substantia nigra: effects of medial forebrain bundle lesions. Brain Res. 645, 98 102.
76. Yokel R., Allen D., Burgio D. McNamara P. (1992) Antipyrine as a dialyzable reference to correct differences in efficiency among and within sampling devices during in vivo microdialysis. J. Pharmacol. Toxicol. Methods 27, 135 142.
77. Zigmond M., Acheson A., Stachowiak M. Stricker E. (1984) Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch. Neurol. 41, 856 861.
78. Zigmond M., Abercrombie E., Berger T., Grace A. Stricker E. (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13, 290 296.